Literature DB >> 21784902

TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29.

Wei Qin1, Arthur C K Chung, Xiao R Huang, Xiao-Ming Meng, David S C Hui, Cheuk-Man Yu, Joseph J Y Sung, Hui Y Lan.   

Abstract

TGF-β/Smad3 signaling promotes fibrosis, but the development of therapeutic interventions involving this pathway will require the identification and ultimate targeting of downstream fibrosis-specific genes. In this study, using a microRNA microarray and real-time PCR, wild-type mice had reduced expression of miR-29 along with the development of progressive renal fibrosis in obstructive nephropathy. In contrast, Smad3 knockout mice had increased expression of miR-29 along with the absence of renal fibrosis in the same model of obstruction. In cultured fibroblasts and tubular epithelial cells, Smad3 mediated TGF-β(1)-induced downregulation of miR-29 by binding to the promoter of miR-29. Furthermore, miR-29 acted as a downstream inhibitor and therapeutic microRNA for TGF-β/Smad3-mediated fibrosis. In vitro, overexpression of miR-29b inhibited, but knockdown of miR-29 enhanced, TGF-β(1)-induced expression of collagens I and III by renal tubular cells. Ultrasound-mediated gene delivery of miR-29b either before or after established obstructive nephropathy blocked progressive renal fibrosis. In conclusion, miR-29 is a downstream inhibitor of TGF-β/Smad3-mediated fibrosis and may have therapeutic potential for diseases involving fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784902      PMCID: PMC3148701          DOI: 10.1681/ASN.2010121308

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  34 in total

1.  Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice.

Authors:  A Nakao; M Fujii; R Matsumura; K Kumano; Y Saito; K Miyazono; I Iwamoto
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

2.  Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response.

Authors:  G S Ashcroft; X Yang; A B Glick; M Weinstein; J L Letterio; D E Mizel; M Anzano; T Greenwell-Wild; S M Wahl; C Deng; A B Roberts
Journal:  Nat Cell Biol       Date:  1999-09       Impact factor: 28.824

3.  Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation.

Authors:  Kathleen C Flanders; Catherine D Sullivan; Makiko Fujii; Anastasia Sowers; Mario A Anzano; Alidad Arabshahi; Christopher Major; Chuxia Deng; Angelo Russo; James B Mitchell; Anita B Roberts
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

4.  Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Jingsong Zhao; Wei Shi; Yan-Ling Wang; Hui Chen; Pablo Bringas; Michael B Datto; Joshua P Frederick; Xiao-Fan Wang; David Warburton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-03       Impact factor: 5.464

5.  Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta.

Authors:  X Yang; J J Letterio; R J Lechleider; L Chen; R Hayman; H Gu; A B Roberts; C Deng
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

6.  Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3.

Authors:  K Yagi; D Goto; T Hamamoto; S Takenoshita; M Kato; K Miyazono
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

7.  Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model.

Authors:  Hui Y Lan; Wei Mu; Naruya Tomita; Xiao R Huang; Jin H Li; Hong-Jian Zhu; Ryuichi Morishita; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

8.  Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.

Authors:  M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

9.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.

Authors:  A B Kulkarni; C G Huh; D Becker; A Geiser; M Lyght; K C Flanders; A B Roberts; M B Sporn; J M Ward; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

10.  Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.

Authors:  Misako Sato; Yasuteru Muragaki; Shizuya Saika; Anita B Roberts; Akira Ooshima
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

View more
  232 in total

1.  Transforming growth factor-β induces microRNA-29b to promote murine alveolar macrophage dysfunction after bone marrow transplantation.

Authors:  Racquel Domingo-Gonzalez; Carol A Wilke; Steven K Huang; Yasmina Laouar; Jeanette P Brown; Christine M Freeman; Jeffrey L Curtis; Gregory A Yanik; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

2.  Managing microvascular complications of diabetes with microRNAs.

Authors:  Shawn S Badal; Farhad R Danesh
Journal:  J Am Soc Nephrol       Date:  2012-01-12       Impact factor: 10.121

Review 3.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

Review 4.  Smad-mediated regulation of microRNA biosynthesis.

Authors:  Matthew T Blahna; Akiko Hata
Journal:  FEBS Lett       Date:  2012-01-28       Impact factor: 4.124

Review 5.  MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 6.  Modulation of immune responses following solid organ transplantation by microRNA.

Authors:  Nayan J Sarma; Venkataswarup Tiriveedhi; Sabarinathan Ramachandran; Jeffrey Crippin; William Chapman; T Mohanakumar
Journal:  Exp Mol Pathol       Date:  2012-10-01       Impact factor: 3.362

7.  microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.

Authors:  Soumya Maity; Amit Bera; Nandini Ghosh-Choudhury; Falguni Das; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  Exp Cell Res       Date:  2018-02-01       Impact factor: 3.905

8.  Post-transcriptional regulation in osteoblasts using localized delivery of miR-29a inhibitor from nanofibers to enhance extracellular matrix deposition.

Authors:  Eric N James; Anne M Delany; Lakshmi S Nair
Journal:  Acta Biomater       Date:  2014-05-09       Impact factor: 8.947

9.  Transforming growth factor β-regulated microRNA-29a promotes angiogenesis through targeting the phosphatase and tensin homolog in endothelium.

Authors:  Jun Wang; Youliang Wang; Yu Wang; Ying Ma; Yu Lan; Xiao Yang
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

10.  Pregnancy-driven cardiovascular maternal miR-29 plasticity in obesity.

Authors:  N Schlabritz-Loutsevitch; K Apostolakis-Kyrus; R Krutilina; G Hubbard; M Kocak; Z Janjetovic; S Sathanandam; A T Slominski; G Mari; E Dick
Journal:  J Med Primatol       Date:  2016-09-15       Impact factor: 0.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.